Girentuximab Vedotin Biosimilar - Research Grade

Human

CA9 / Carbonic anhydrase 9

1mg/ml

IgG1

CHO Cells

Q16790

Room Temp

Carbonic anhydrase 9 (CA9) is a hypoxia-associated tumour antigen frequently exploited for targeted delivery in oncology research. This research-grade reagent is an unconjugated, non-therapeutic vedotin-format analog directed at human CA9, intended as a defined tool for antibody-drug conjugate studies and validated for functional assays. It is provided for research use only, formulated to a low-endotoxin standard suitable for in vivo work, and produced in scalable milligram to gram quantities for high-throughput laboratories. Typical applications include payload-delivery and internalisation studies, in vitro cytotoxicity screening, in vivo tumour models, and ADC development workflows.

MMAE

25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

1 week